Form 4: Frankenius Equity AB Acquires 62,972 Shares of TriSalus Life Sciences, Inc.

Frankenius Equity AB, a 10% owner of TriSalus Life Sciences, Inc., acquired 62,972 shares of common stock at $3.97 per share on December 17, 2024.

Summary

• Frankenius Equity AB, a significant shareholder of TriSalus Life Sciences, Inc., has reported the acquisition of 62,972 shares of common stock.
• The transaction occurred on December 17, 2024, with the shares purchased at a price of $3.97 each.
• This purchase increases Frankenius Equity AB's direct holdings to 6,230,748 shares.
• The shares were issued as part of the closing of a transaction under a Securities Purchase Agreement dated December 12, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a major shareholder's continued investment in the company, suggesting confidence in its future prospects.

Positives

• The acquisition demonstrates a continued investment by a major shareholder in TriSalus Life Sciences, Inc.
• The purchase of shares at $3.97 indicates confidence in the company's value.

Industry Context

This transaction reflects ongoing investment activity in the life sciences sector, where strategic acquisitions and ownership changes are common.

Comparison to Industry Standards

• Share acquisitions by major shareholders are a common occurrence in the biotech and life sciences industry.
• Similar transactions can be seen with companies like Xencor and BioMarin, where large shareholders often increase their stakes.
• The size of this acquisition is relatively small compared to some major institutional investments, but it is significant for a 10% owner.

Stakeholder Impact

• The increased shareholding by Frankenius Equity AB could be viewed positively by other shareholders, potentially increasing confidence in the company's future.

Key Dates

Keywords

TriSalus Life Sciences, Frankenius Equity AB, share acquisition, common stock, securities purchase agreement, beneficial ownership